Sperry JL, Guyette FX, Brown JB, et al. Prehospital Plasma during Air Medical Transport in Trauma Patients at Risk for Hemorrhagic Shock. N Engl J Med. 2018 Jul 26;379(4):315-326 : Hier gehts zum Link
Stellungnahme PD Dr. H. Schöchl et al:
In the PAMPer trial, prehospital low-dose plasma appeared beneficial for trauma patients.1 Mortality rates were 23% in the plasma group and 33% in the standard care group, while median injury severity scores (ISS) were 21 and 22, respectively. In contrast, a similar study by Moore et al. showed no survival benefit with prehospital plasma.2 In the Moore et al. study, and in the RETIC study of coagulation factor concentrates in trauma, mortality rates (4–15%) were lower than in PAMPer, despite higher ISS (27–35). 2,3 These findings raise questions regarding quality of care in PAMPer.
Prehospital plasma had no significant impact on TEG parameters in the PAMPer trial. A statistically significant between-group difference in prothrombin-time ratio was observed but, because median values were numerically similar (1.2 vs. 1.3), the clinical significance is questionable. Trauma patients may not require increased INR4 and, in any case, therapeutic plasma is acknowledged to have limited effectiveness in this regard. 5 The lower mortality in the plasma group is more likely attributable to increased circulation volume than improved coagulation.
Letzte Aktualisierung am 15.11.2018